Subconjunctival filtration in evolution: current evidence on MicroShunt implantation for treating patients with glaucoma.

"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationNot applicable. Competing interestsIke Ahmed has the following disclosures: Aequus: C; Aerie Pharmaceuticals: C, R; Akorn: C; Alcon: C, S, R; Allergan: C, S, R; Aquea Health, Inc: C; ArcScan: C; Avisi: C; Bausch Health: C; Beaver Visitec: C; Beyeonics: C; Bionode: C, R; Carl Zeiss Meditec: C, S; Centricity Vision, Inc: C; CorNeat Vision: C; Custom Surgical: C; Elios Vision: C; ElutiMed: C; Equinox: C; eyeFlow, Inc: C; Genentech: C; Glaukos: C, R; Gore: C; Heine: C, S; Heru: C; Iantrek: C; InjectSense: C; Iridex: C; iCare: R; iStar: C; Ivantis: C, R; Johnson & Johnson Vision: C, S, R; Labtician Thea: C; LayerBio: C; Leica Microsystems: C; Life Long Vision: C; Long Bridge Medical, Inc: C; MicroOptx: C; MST Surgical: C, S; Myra Vision: C; New World Medical: C, R; Ocular Instruments: C; Ocular Therapeutix: C; Oculo: C; Omega Ophthalmics: C; PolyActiva: C; PulseMedica: C; Radiance Therapeutics, Inc: C; Ripple Therapeutics: C; Sanoculis: C; Santen: C, R; Shifamed, LLC: C. Sight Sciences: C; Smartlens, Inc: C; Stroma: C; Thea Pharma: C; ViaLase: C; Visus Therapeutics: C; Vizzario: C; VSY Biotechnology: C; Zilia, Inc: C. Joseph F. Panarelli has the following disclosures: Aerie Pharmaceuticals: C; Allergan: C, R; CorneaGen: C; Glaukos: C; New World Medical: C; Santen: C. Omar Sadruddin was an employee of Santen, Inc. at the time of manuscript submission. Currently, he is employed at Glaukos Corporation. C – consultant/consulting fees; S – speakers honoraria; R – research grant/support. Competing interests Ike Ahmed has the following disclosures: Aequus: C; Aerie Pharmaceuticals: C, R; Akorn: C; Alcon: C, S, R; Allergan: C, S, R; Aquea Health, Inc: C; ArcScan: C; Avisi: C; Bausch Health: C; Beaver Visitec: C; Beyeonics: C; Bionode: C, R; Carl Zeiss Meditec: C, S; Centricity Vision, Inc: C; CorNeat Vision: C; Custom Surgical: C; Elios Vision: C; ElutiMed: C; Equinox: C; eyeFlow, Inc: C; Genentech: C; Glaukos: C, R; Gore: C; Heine: C, S; Heru: C; Iantrek: C; InjectSense: C; Iridex: C; iCare: R; iStar: C; Ivantis: C, R; Johnson & Johnson Vision: C, S, R; Labtician Thea: C; LayerBio: C; Leica Microsystems: C; Life Long Vision: C; Long Bridge Medical, Inc: C; MicroOptx: C; MST Surgical: C, S; Myra Vision: C; New World Medical: C, R; Ocular Instruments: C; Ocular Therapeutix: C; Oculo: C; Omega Ophthalmics: C; PolyActiva: C; PulseMedica: C; Radiance Therapeutics, Inc: C; Ripple Therapeutics: C; Sanoculis: C; Santen: C, R; Shifamed, LLC: C. Sight Sciences: C; Smartlens, Inc: C; Stroma: C; Thea Pharma: C; ViaLase: C; Visus Therapeutics: C; Vizzario: C; VSY Biotechnology: C; Zilia, Inc: C. Joseph F. Panarelli has the following disclosures: Aerie Pharmaceuticals: C; Allergan: C, R; CorneaGen: C; Glaukos: C; New World Medical: C; Santen: C. Omar Sadruddin was an employee of Santen, Inc. at the time of manuscript submission. Currently, he is employed at Glaukos Corporation. C – consultant/consulting fees; S – speakers honoraria; R – research grant/support."

"Funding This study was funded by Santen, Inc."